

A Randomized controlled trial to compare effectiveness and side-effects of Brinzolamide and Dorzolamide among patients with high intra-ocular pressure

Sushma Kumari Singhal¹, Prerna Agarwal², Rohit Kumar Yogi³, Ritu Agarwal⁴

¹Assistant Professor, Department of Ophthalmology, Ananta Institute of Medical Sciences & Research Centre, Rajsamand, Rajasthan, India

²Associate Professor, Department of ophthalmology, Ananta Institute of Medical Sciences & Research centre, Rajsamand, Rajasthan, India

³Assistant Professor, Department of Ophthalmology, Ananta Institute of Medical Sciences & Research Centre, Rajsamand, Rajasthan, India

⁴Assistant Professor, Department of Ophthalmology, American International Institute of Medical Sciences, Udaipur, Rajasthan, India

Received: 03-11-2021 / Revised: 26-12-2021 / Accepted: 15-01-2022

Abstract

Primary open angle glaucoma [POAG] is a chronic, progressive optic neuropathy in adults in which intraocular pressure (IOP) and other currently unknown factors contribute to damage of optic nerve. Reduction of elevated intraocular pressure is the only as yet proven approach to protect against visual field loss in patients with primary open angle glaucoma or ocular hypertension. First line therapy for elevated IOP is typically is a single topical agent like dorzolamid and brinzolamide. **Aim:** to compare effectiveness of dorzolamide and brinzolamide in lowering IOP. **Methodology:** This was a randomized controlled trial conducted at the Department of Ophthalmology, Jawahar Lal Nehru hospital, Ajmer, Rajasthan during the period from April 2017 to April 2018. A total of 52 patients (104 eyes) were initially enrolled in the study. **Results:** Topical brinzolamide 1% is found to be better than dorzolamide 2% as monotherapy for POAG and ocular hypertension as initial drug due to lower side effect and equal efficacy. **Conclusion :** The results of this study also indicate that both brinzolamide bid and dorzolamide t.i.d produced a clinically significant and equivalent lowering IOP in a large percentage of patients.

Keywords: Primary open angle glaucoma, intraocular pressure, brinzolamide, dorzolamide.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Glaucoma is word that does not refer to a single disease entity, but rather a group of disease that defer in their clinical presentation, pathophysiology and treatment[1]. Primary open angle glaucoma is a chronic, progressive optic neuropathy in adults in which intraocular pressure (IOP) and other currently unknown factors contribute to damage of optic nerve. It is estimated that 45 million people in the world have open-angle glaucoma (OAG)[2]. Glaucoma (both open-angle and angle closure) is the second leading cause of blindness worldwide, with approximately 8.4 million people blind from glaucoma. There are approximately 11.2 million persons aged 40 years and older with glaucoma in India[3]. The overall prevalence of OAG in the US population 40 years and older is estimated to be 1.86% (95% confidence interval, 1.75%-1.96%)[4]. A study shows that prevalence of POAG and OHT is more in older age group latinos than younger, there is no gender related differences in prevalence of POAG and OHT[5,6]. Glaucomatous visual changes and defects are irreversible because of retinal ganglion nerve cell damage. Due to the irreversible nature of glaucomatous defects, current strategy aims at early detection through screening, and further detailed examination of 'at risk' suspects[7,8]. The changes of primary open angle glaucoma are noticed by the patient after significant disease progression due to a relative lack of attendant alerting symptoms. These factors make glaucoma the 'sneak thief' of vision. Hence the need for early diagnosis, prompt treatment

and lifelong compliance. Glaucoma is detected by means of a detailed eye examination including visual acuity, visual field testing for peripheral vision, dilated eye examination for inspecting the optic nerve for any signs of damage, tonometry for measuring IOP and specular microscopy for measuring central corneal thickness.

Reduction of elevated intraocular pressure is the only as yet proven approach to protect against visual field loss in patients with primary open angle glaucoma or ocular hypertension[7,8]. First line therapy for elevated IOP is typically is a single topical agent, belonging to one of the following classes of drugs: Prostaglandin analogues /derivatives, Beta blockers, Alpha-2adrenergic receptor agonists, and carbonic anhydrase inhibitors. Dorzolamide, a carbonic anhydrase inhibitor, was FDA approved in 1994[9] for the treatment of elevated intraocular pressure of primary open angle glaucoma and ocular hypertension, is also associated with significant side effects such as ocular burning, stinging, allergic reaction, superficial punctate keratitis and others[10]. Brinzolamide is another carbonic anhydrase inhibitor launched more recently, FDA approved in 1998 for the treatment of elevated intraocular pressure in primary open angle glaucoma and ocular hypertension[11].

There is paucity of studies comparing efficacy and side effect profile of dorzolamide and brinzolamide head to head, in the Indian population, the present is an attempt in that direction.

Objectives:

1. To compare the IOP lowering ability of topical brinzolamide 1% and dorzolamide 2% monotherapy
2. To compare the side effect profile of topical brinzolamide and dorzolamide monotherapy.

Methodology

This was a prospective, randomized, active controlled, parallel group study done by double blinding, conducted at the Department of Ophthalmology, Jawahar Lal Nehru hospital, Ajmer, Rajasthan during

*Correspondence

Dr. Ritu Agarwal

Assistant Professor, Department of Ophthalmology, American International Institute of medical sciences, Udaipur, Rajasthan, India.

E-mail: agarwal.dr.ritu.09@gmail.com

the period from April 2017 to April 2018. A total of 52 patients (104 eyes) were initially enrolled in the study, according to the following criteria-

Inclusion Criteria

1. Above 35 years of age, of any race and either sex.
2. Diagnosed with either primary open angle glaucoma or ocular hypertension, in at least one eye.
3. Best corrected visual acuity better than 6/24 in the study eye.
4. The IOP in the study eye must have been considered controllable on one drug therapy in such a way that should assure clinical stability of vision and optic nerve through the trial.

Exclusion criteria: Patients with conjunctivitis, keratitis, uveitis, scleritis, any local abnormality, chronic or recurrent inflammatory eye disease, hypersensitivity to medication, pregnant, any severe medical or surgical condition, intra-ocular surgery in last 3 months, progressive retinal disease or on therapy that affect IOP or systemic blood pressure were excluded from the study. Informed consent was taken from all participants enrolled in the study.

Patient Examination

VISIT 0: Preliminary assessment and examination including detailed history and comprehensive medical examination [visual acuity, anterior segment slit lamp microscopic examination, gonioscopy, IOP determination].

VISIT 1: Pre-randomization assessment Baseline this involved baseline visual analogue pain/discomfort score assessment and central corneal thickness measurements with Specular microscope.

Randomization: Subjects were randomized using a random number table generator, into 2 groups:

Group A: Received topical brinzolamide 1% monotherapy twice daily (8 am and 10 pm) for a period of three months, and

Group B: Received topical dorzolamide 2% monotherapy thrice daily (8 am, 3 pm and 10 pm) for a period of three months.

Visit 2: 3 weeks post-randomization assessment- The subjects were inquired regarding the development of any new ocular or systemic symptoms/side effects, routine follow-up best corrected vision (Snellen’s) assessment, central corneal thickness measurements and Visual analogue ocular discomfort score [This score was done before administration of ocular medication, 2 minutes after administration of ocular medication at the health facility]. Diurnal variation IOP was measured with the Goldmannapplanation tonometer with the patient sitting, at 9am, 1pm, 5pm and 9pm(before medication instillation).

Visit 3: at 3 months post-randomization assessment- The subjects were assessed similar to the assessment done in Visit 2.

Results

A total of 52 patients were initial enrolled in the study and were randomly assigned to treatment. All 52 received at least 1 week of medication in both eyes. Two patients were not available for follow-up assessments and were withdrawn from the study. Both eyes of all remaining 50 patients qualified for the purpose of the study. So a total 50 patients (100 eyes) with 25 patients in each group, completed the entire study period, and were included in the final analyses. Each individual eye was treated as a statistical unit for the purposes of the study.

Table 1: Patient Demographics

| | Patient Demographics (No. {%}) | | |
|----------------------|------------------------------------|-----------------------------------|-----------------------|
| | Brinzolamide Group (n=25 patients) | Dorzolamide Group (n=25 patients) | Total (n=50 patients) |
| Sex | | | |
| Male | 13(52%) | 14(56%) | 27(54%) |
| Female | 12(48%) | 11(44%) | 23(46%) |
| Age | | | |
| 31 – 40 years | 1 | 0 | 1 |
| 41 – 50 years | 4(16%) | 6(24%) | 10(20%) |
| 51 – 60 years | 7(28%) | 7(28%) | 14(28%) |
| 61 – 70 years | 10(40%) | 10(40%) | 20(40%) |
| 71 – 80 years | 3(12%) | 2(8%) | 5(10%) |
| Ocular Hypertensives | 11(44%) | 10(40%) | 21(42%) |
| POAG | 14(56%) | 15(60%) | 29(58%) |

The mean age in brinzolamide group was 60.2 yrs and 59.48 yrs in the dorzolamide group, so the mean age of patients in the study was 59.84 yrs. In each group, the maximum number of patients were in the 51-70yrs (68%) age group. In group A (brinzolamide), 44% of the patients had ocular hypertension, and 56% of the patients had POAG, while in group B (dorzolamide), 40% of the patients had ocular hypertension, and 60% of the patients had POAG. There was no statistically difference among the two groups (p>>0.05).

Baseline Intraocular Pressure

For each patient, average IOP at baseline, average IOP at 3 weeks, and average IOP at 3 months was calculated. The mean of the IOP’s was also calculated for each visit. No statistically significant differences were observed between the two groups with respect to mean IOP at baseline, or diurnal variation (p>0.05 unpaired t-test).

Intergroup comparisons

Each individual IOP measurement by time of day, at visits 2 (3 weeks) and 3(3 months) was compared with the IOP measurements at baseline. This was used to calculate the mean change in IOP (mmHg) for each treatment group by visit (2 and 3) and time of day (9am, 1pm, 5m, 9pm,) for each group. [Table 2].The mean IOP after 3 weeks was 19.73 mmHg and 19.64 mmHg for the brinzolamide and dorzolamide groups respectively and after 3 months, the mean IOP was 19.40 mmHg and 19.34 mmHg in the two groups were compared, which showed that there was no statistically significant difference (p>0.05) between them (Table 2), this infers that the maximum IOP lowering effect achieved within 3weeks.

Table 2: Mean IOP by Visit and Time of Day

| | Brinzolamide | S.D | Dorzolamide | S.D | Unpaired t test (p value) |
|-----------------|--------------|------|-------------|------|---------------------------|
| | Mean | | Mean | | |
| Baseline | | | | | |
| 9am | 25.26 | 1.52 | 25.22 | 1.55 | 0.897 |
| 1pm | 24.02 | 1.80 | 24.1 | 1.98 | 0.833 |
| 5pm | 23.24 | 2.74 | 23.52 | 2.52 | 0.596 |

| | | | | | |
|----------------|-------|------|-------|------|-------|
| 9pm | 23.00 | 2.66 | 23.04 | 2.50 | 0.938 |
| Avg | 23.88 | 2.18 | 23.97 | 1.96 | 0.818 |
| 3weeks | | | | | |
| 9am | 20.42 | 1.50 | 20.46 | 1.56 | 0.897 |
| 1pm | 19.52 | 1.68 | 19.74 | 1.81 | 0.531 |
| 5pm | 19.84 | 2.31 | 19.26 | 1.97 | 0.180 |
| 9pm | 19.16 | 1.88 | 19.12 | 1.78 | 0.913 |
| Avg | 19.74 | 1.84 | 19.64 | 1.61 | 0.786 |
| 3months | | | | | |
| 9am | 19.52 | 1.71 | 19.76 | 1.73 | 0.698 |
| 1pm | 19.7 | 1.71 | 19.5 | 1.72 | 0.582 |
| 5pm | 19.34 | 2.03 | 19.16 | 1.93 | 0.454 |
| 9pm | 19.06 | 2.32 | 18.96 | 2.04 | 0.229 |
| Avg | 19.40 | 1.94 | 19.34 | 1.66 | 0.172 |

Analysis of Ocular Side Effects

The most frequent adverse events reported included ocular discomfort (typically characterized as pain and burning sensation), transient

blurred vision, conjunctivitis, and taste abnormality. The incidence of ocular discomfort was significantly less in the brinzolamide group (8%) versus the dorzolamide group (28%).

Table 3: Side effect profile of two drugs

| Side Effect Incidences No. (%) | Brinzolamide group (n=25 pts) | Dorzolamide group (n=25 pts) |
|--------------------------------|-------------------------------|------------------------------|
| Pain and burning sensation | 2 (8%) | 6 (24%) |
| Transient Blurred vision | 1 (4%) | 0 |
| Conjunctivitis | 0 | 1 (4%) |
| Taste abnormality | 2 (8%) | 1 (8%) |
| Foreign body sensation | 1 (4%) | 1 (4%) |
| Tearing | 0 | 2 (8%) |

The baseline visual analog scale scores were comparable among both the groups, as was also revealed by the significance value (>>0.05). The mean discomfort scores immediately post installation at 3week and 3month was 5.8 and 4.5 respectively and chronic score was 5.02 and 3.7 for brinzolamide group compared with dorzolamide group in which immediate post installation score at 3week and 3month was 13.34 and 11.6 and chronic score was 11.80 and 10.14 showed that ocular discomfort score were significantly (p-value<0.05) lower in brinzolamide group in comparison to dorzolamide group.

Discussion

This study was undertaken to compare the efficacy and side effect profile of the two commercially available topical carbonic anhydrase inhibitors, Brinzolamide and Dorzolamide, in an Indian population, when used as monotherapy. Mean age in brinzolamide group was 60.2yrs and 59.48yrs in dorzolamide group, so the mean age of patients in study was 59.84yrs. These finding were supported by Hollo G et al[12] where the mean age of POAG and OHT patients were 68.8±15.3yrs and 60.3±12.6yrs respectively, which correlate with our finding that POAG and OHT is more common in people of more than 40yrs of age. The IOP-lowering efficacy of brinzolamide twice daily (administered at 8 am and 10 pm) was demonstrated by both clinically relevant and statistically significant IOP reductions at all the times of day measured. Mean baseline IOP of brinzolamide group was 23.88mmHg was compared with mean IOP at 3months 19.40mmHg (p-value<0.001) which shows a statistically significant reduction (Table 2). A study conducted by Wang TH; Huang JY; Hung PT(2004) et al showed that after 6weeks treatment by b.d dosing of topical brinzolamide 1% IOP 17% reduction (drooped by 4.8mmHg) achieved. Similarly, the IOP-lowering effects of dorzolamide thrice daily (administered at 8 am, 3 pm and 10 pm) was demonstrated by both clinically relevant and statistically significant IOP reductions at all times. Mean baseline IOP of dorzolamide group was 23.97mmHg was compared with mean IOP at 3months which was 19.34mmHg (p-value<0.001) showed a statistically significant reduction in IOP[13,14] A study by Wilkerson M; Cyrilin M; Lippa EA (1993) et al showed that 18.4% (mean baseline 26.8mmHg and after 4weeks mean IOP 21.8mmHg) reduction in IOP achieved in 4weeks with 2% dorzolamide ophthalmic solution. A four week safety and efficacy study of dorzolamide by Wilkerson M, Cyrilin M, Lippa EA(1993) et al showed that 18.4%(mean baseline 26.8mmHg and

after 4weeks mean IOP 21.8mmHg) reduction in IOP achieved in 4weeks revealing statistically significant(p<0.05) reduction in IOP in 4weeks. The incidence of ocular discomfort was significantly less in the brinzolamide group (8%) versus the dorzolamide group (28%) (Table 3). In study of Tuskamoto H, Noma H, Mukai S(2005) et al[15] incidence of ocular irritation was significantly higher (p-value<0.0001) in dorzolamide group (74%) than brinzolamide group (16%), which shows that dorzolamide causes more ocular discomfort than brinzolamide. The mean pain/discomfort score after intervention was found to be significantly higher in the dorzolamide group (p<0.05 at each follow up visit) vs the brinzolamide group. The visual analogue scale is a validated scale that has been described previously for ocular use. Shin D (2000); Silver, L.H.(1998); Sall K(2000) et al study have evaluated the safety of brinzolamide 1% compared with dorzolamide 2% ophthalmic suspension and concluded both brinzolamide and dorzolamide have equivalent efficacy for lowering elevated IOP[16-20]

Conclusion

The results of this study also indicate that both brinzolamide bid and dorzolamide t.i.d produced a clinically significant and equivalent lowering IOP in a large percentage of patients. We recommend topical brinzolamide 1% over dorzolamide 2% as monotherapy for POAG and OHT as initial drug due to lower side effect and equal efficacy.

References

1. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® Guidelines: Primary Open-Angle Glaucoma. San Francisco, CA: American Academy of Ophthalmology, 2010. Available at: www.aao.org/ppp.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7.
3. Weinreb RN, Khaw PT et al. Primary open angle glaucoma. Lancet. 2004;363:1711-172.
4. Friedman DS, Wolfs RC, O'Colmain BJ et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol, 2004;122:532-8.
5. Varma R, Ying-Lai M, Francis BA et al. Los Angeles Latino Eye Study Group. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111:1439-48.

6. Sommer A, Tielsch JM, Katz J et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. *N Engl J Med.* 1991;325:1412-7.
7. AGIS investigators AGIS 7. The relationship between control of IOP and visual field deterioration. *Am J Ophthalmol.* 2000;130:429-40.
8. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO. For the Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002;120:701-713
9. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Trusopt NDA 20408/S033 approval letter, April 15, 2004. Retrieved August 24, 2011 from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020408_S033_TRUSOPT.pdf
10. Allingham RR, Damji KF, Freedman S, Moroi SE, Rhee DJ. Carbonic Anhydrase Inhibitors. In: Shields textbook of Glaucoma. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins. 2011;31:430-431.
11. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Azopt NDA 20816 approval letter, April 1, 1998. Retrieved August 24, 2011 from http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20816_AZOPT_APPROV.PDF
12. Hollo G, Chiselita D, Petkova N et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. *Eur J Ophthalmol.* 2006;16:816-23.
13. Wang TH, Huang JY, Hung PT et al. Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. *J Formos Med Assoc.* 2004;103:369-73.
14. Wilkerson M, Cyrilin M, Lippa EA, Esposito D, Deasy D, Panebianco D et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. *Arch Ophthalmol.* 1993;111:1343.
15. Tsukamoto H, Noma H, Mukai S, Ikeda H, Mishima HK. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. *J Ocul Pharmacol Ther.* 2005;21(5):395-9.
16. Scoville B, Kriegelstein GK, Then E, Yokoyama S, Yokoyama T. Measuring drug-induced eye irritation: a simple new clinical assay. *J Clin Pharmacol.* 1985;25:210-218.
17. Price DD, Mcgrath PA, Raffi A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. *Pain.* 1983;17:45-56.
18. Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. *Surv Ophthalmol.* 2000;44(Suppl 2):S163-S168.
19. Silver LH. Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. *Am J Ophthalmol.* 1998; 126(3):400-8.
20. Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. *Surv Ophthalmol.* 2000;44(Suppl 2):S155-S162.

Conflict of Interest: Nil

Source of support: Nil